DSM-Firmenich Reclassifies ANH Activities as Discontinued Operations
DSM-Firmenich announces the accounting reclassification of its Animal Nutrition & Health (ANH) activities as discontinued operations following the divestiture to CVC Capital Partners. This action is accompanied by a restructuring of the group's financial presentation.
Reclassification and Sector Restructuring
Following the announced divestiture of the Animal Nutrition & Health activities to CVC Capital Partners, DSM-Firmenich has reclassified the assets and liabilities of the divested sector as Assets Held for Sale. The financial results of the ANH activities are now presented as Discontinued Operations. Concurrently, the group is undergoing a major restructuring of its sector presentation: Perfumery & Beauty (P&B) has been restated for Aroma Ingredients and Pentapharm, transferred to discontinued operations; Taste, Texture & Health (TTH) incorporates Bovaer from ANH; Health, Nutrition & Care (HNC) welcomes Veramaris, transferred from ANH. The discontinued operations include ANH (including feed enzymes sold in June 2025), Aroma Ingredients, Marine Lipids, Yeast Extracts, and certain non-differentiated vitamin products.
Restatement of Comparative Figures
DSM-Firmenich will restate its comparative figures for the last four reported quarters (Q4 2024, Q1 2025, Q2 2025, Q3 2025) as well as for the full fiscal year 2024, covering net sales, Adjusted EBITDA, Adjusted EBITDA margin, and organic sales growth. The group introduces an adjusted 'Core EBIT' indicator incorporating the reintegration of depreciation related to the merger and amortization of intangible assets from prior purchase price allocations. The complete 2025 results will be published on February 12, 2026, under this new classification. Starting from the first quarter of 2026, the Nutrition Improvement activities, generating approximately 20 million euros in quarterly net sales and operating at break-even at the Adjusted EBITDA level, will be transferred from HNC to corporate activities.
No Financial Evaluation Provided
The press release does not provide a financial evaluation of the divestiture price of the ANH division nor an estimate of the impact on future results. The complete restatements of the 2024 income statement will be communicated during the publication of the annual results 2025 on February 12, 2026. The announced restatement does not yet include changes in presentation related to Nutrition Improvement.
